ZSFab
Developing patient-specific orthopedic and spinal implants, surgical guides, and anatomical models using 3D printing.
Website: https://www.zsfab.com/
Cover Block
Open sources
| Field | Detail |
|---|---|
| Name | ZSFab |
| Tagline | Developing patient-specific orthopedic and spinal implants, surgical guides, and anatomical models using 3D printing. |
| Headquarters | Waltham, Massachusetts, USA [Crunchbase, retrieved 2026] |
| Founded | 2017 [Crunchbase, retrieved 2026] |
| Stage | Seed [Crunchbase, retrieved 2026] |
| Business model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (2), Jing Zhang and Kai X. [Swissnex, February 2022] [Caplight, retrieved 2026] |
| Funding label | Seed |
| Total disclosed | Approximately $2.5 million [CB Insights, retrieved 2026] |
Links
Open sources
- Website: https://www.zsfab.com/
- LinkedIn: https://www.linkedin.com/company/zsfab
What an Investor Needs First
PUBLIC ZSFab is a Waltham, Massachusetts medical device startup developing patient-specific orthopedic and spinal implants, surgical guides, and anatomical models with 3D printing, and it merits attention now because public evidence points to an active U.S. commercialization push in spinal interbody cages after modest seed financing [LinkedIn, retrieved 2026] [ZSFab, October 2026] [CB Insights, retrieved 2026]. Founded in 2017, the company appears to have spent its early years building around customized implant design and additive manufacturing, then moved more visibly into spinal applications, with its careers page and product materials centering lumbar TLIF/PLIF and cervical ACDF cages for the U.S. market [Swissnex, February 2022] [ZSFab, October 2026] [ZSFab, retrieved 2026].
The core bet is that software-driven design and 3D-printed architecture can produce implants tailored to anatomy and surgical need, with ZSFab stating that its systems are designed for bone integration, lower stress shielding, and postoperative image clarity; those performance claims remain company-sourced, but they are directionally consistent with the positioning of porous titanium spine implants more broadly [ZSFab, retrieved 2026]. Publicly cited product categories extend beyond spine to hip implants, acetabular cups, vertebral-body implants, surgical guides, and anatomical models, which suggests a wider platform ambition even as current hiring language points to spine as the commercial wedge [CB Insights, retrieved 2026] [ZSFab, October 2026].
On the team, founder and CEO Jing Zhang is described by Swissnex as having worked in 3D-printing R&D, technology, and market development since 2007 and as having become a full-time entrepreneur in 2016 after investment experience, which gives the company a founder profile that is more technical-commercial than purely clinical [Swissnex, February 2022]. Kai X., identified as CTO and co-founder in company database profiles, appears to anchor the technical side, although public biographical detail on him is thin in the available record [Caplight, retrieved 2026] [Kai Xu - Graduate Intern (thesis) - Turner & Townsend | LinkedIn, retrieved 2026].
Financing looks early by medtech standards: Caplight records a $2.48 million seed round on September 22, 2021 led by Celtic House Asia Partners, while CB Insights reports roughly $2.5 million in total disclosed funding, with investors including Foothill Ventures, Ferry Venture Capital, Tsing-Yuan Capital, Taihill Venture, and iVision Ventures [Caplight, retrieved 2026] [CB Insights, retrieved 2026]. That capital base is small relative to established spine-device peers, which likely explains the narrow commercialization focus and the importance of disciplined surgeon adoption, regulatory execution, and channel buildout over the next 12 to 18 months [ZSFab, October 2026] [BioSpace, April 2023] [Synapse, June 2024].
The near-term watch items are straightforward: whether company-announced clinical use cases in cervical and lumbar systems translate into repeatable U.S. deployment, whether the current sales and instrument-development hiring converts into a visible go-to-market footprint, and whether independent evidence emerges on surgeon uptake or hospital adoption [BioSpace, April 2023] [Yahoo Finance, retrieved 2026] [Synapse, June 2024] [ZSFab, October 2026]. For now, the public record supports cautious interest in a technically differentiated spine-implant startup that has cleared at least some early product and commercialization milestones, but still needs more third-party validation on scale, customers, and regulatory breadth [ZSFab, retrieved 2026] [RegMedNet, retrieved 2026].
Claim stands unchecked -- This section relies materially on company-published product and commercialization claims, with partial corroboration from Swissnex, BioSpace, Synapse, CB Insights, and Caplight.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Total disclosed funding of approximately $2.5 million [CB Insights, retrieved 2026] |
Inside the Company
PUBLIC ZSFab presents as a small, specialist medical-device company built around a narrow but commercially legible thesis: use 3D printing and software-led design to make patient-specific orthopedic and spinal implants, along with surgical guides and anatomical models [ZSFab, retrieved 2026] [Crunchbase, retrieved 2026]. Public records place the company in Waltham, Massachusetts, and date its founding to 2017, which matters here because the timeline suggests a long development cycle rather than a rapid software-style launch cadence [Crunchbase, retrieved 2026].
The company website and database profiles are directionally consistent on scope, even if they are thin on operating detail. ZSFab describes its work in plain clinical terms, centered on personalized implants and spine surgery, while Crunchbase frames the business as developing patient-specific orthopedic and spinal implants using 3D printing [ZSFab, retrieved 2026] [Crunchbase, retrieved 2026].
PUBLIC The public milestone trail is limited, but a few waypoints are visible. Crunchbase records the company as founded in 2017, and public funding databases point to seed financing activity in 2017 and again in September 2021, including a disclosed $2.48 More recently, the company website shows an active hiring posture in the U.S., including roles tied to spinal implant instrument development and sales, which indicates that ZSFab is positioning itself as a commercialization-stage device company rather than a research-only platform [ZSFab, retrieved 2026] [ZSFab, October 2026].
That said, the public footprint remains relatively sparse for a business in regulated medtech. The available company materials support the broad outline, founded in 2017, based in greater Boston, focused on personalized spinal and orthopedic implants, but they do not provide the fuller legal and operating detail that institutional investors would usually want early in diligence [ZSFab, retrieved 2026] [Crunchbase, retrieved 2026].
Partially corroborated -- Grounded primarily in company website materials and Crunchbase, with partial chronology support from public company profiles.
Under the Hood
Reported and inferred The product story is narrower than the broader company description first suggests. Public materials describe ZSFab as a developer of patient-specific orthopedic and spinal implants, surgical guides, and anatomical models made with proprietary software, modeling and optimization methods, and 3D printing [LinkedIn] [CB Insights]. The clearest current commercial emphasis, based on the company careers page and website, is spinal interbody-fusion hardware for the U.S. market, specifically lumbar TLIF/PLIF and cervical ACDF cages, alongside related instruments and patient-matched implant design workflows [ZSFab, October 2026] [ZSFab].
The technical differentiation, as presented by the company, rests on architecture control rather than a claim about a novel model layer. ZSFab says its implants are designed to support bone integration, reduce stress shielding, and preserve postoperative imaging clarity, and that it uses digitally structured materials to tune porosity and mechanical properties within the implant geometry [ZSFab]. The company also says proprietary algorithms can generate patient-matched vertebral body implants with customized dimensions, lightweight porous lattice structures, and serration patterns [ZSFab]. Those are company-authored claims, so they speak to intended design logic more than independently verified clinical performance.
Public evidence also suggests the platform has moved beyond concept work into at least early regulated use, although the record remains uneven. ZSFab states that it received FDA 510(k) clearance for a 3D-Printed Lumbar Interbody System and has announced first U.S. clinical use for both its cervical and lumbar interbody systems [ZSFab]. Independent trade and press coverage partially corroborates clinical use claims: BioSpace reported the first U.S. clinical case for the Cervical Interbody System in April 2023, RegMedNet reported two U.S. clinical cases for the ACDF system, Yahoo Finance covered a three-level ACDF procedure in Puerto Rico using the company's 20-degree hyperlordotic cervical cages, and Synapse reported first U.S. clinical use of the InterConnect titanium lumbar system in June 2024 [BioSpace, April 2023] [RegMedNet] [Yahoo Finance] [Synapse, June 2024]. The available public record does not establish adoption scale, named hospital accounts, or comparative outcomes versus incumbent spine-device vendors.
Partially corroborated -- Product scope is supported by company materials and third-party databases, while clinical-use evidence has partial corroboration from named trade and press outlets; several technical and regulatory claims remain company-originated.
Market Research
Open sources The market matters now because spine implants remain a large, steadily growing device category, and the parts of the market ZSFab appears to target, cervical and lumbar interbody cages in North America, sit where procedure volume, reimbursement familiarity, and surgeon demand for differentiated implant geometry already exist [Grand View Research] [MarketsandMarkets].
The cleanest public anchor is the broader spinal implants and devices market. Grand View Research sized the global market at $14.5 billion in 2025 and projects growth to $23.1 billion by 2033, with a 6.1% CAGR from 2026 to 2033 [Grand View Research]. For geography, MarketsandMarkets reported North America held 48.3% of the spinal implants market in 2022 [MarketsandMarkets]. Those figures do not establish ZSFab's precise serviceable market, but they do bound the category in which it operates: a mid-growth medical-device segment with a large U.S. component rather than an experimental niche [Grand View Research] [MarketsandMarkets].
TAM, SAM, and SOM require more caution here than the usual startup deck treatment allows. No cited third-party source in the record provides a ZSFab-specific market cut for patient-specific spinal implants or 3D-printed interbody cages, so a precise TAM/SAM/SOM stack would be speculative. What can be said, based on public evidence, is that ZSFab's stated commercial focus on lumbar TLIF/PLIF and cervical ACDF cages in the U.S. places it inside the dominant product segments of the spine market, according to the company's own market framing, while third-party research supports North America's outsize share of the broader market [ZSFab, October 2026] [ZSFab, retrieved 2026] [MarketsandMarkets].
Global spinal implants market 2025 | 14.5 | $B
Global spinal implants market 2026 | 15.3 | $B
Global spinal implants market 2033 | 23.1 | $B
The chart shows a category with meaningful scale and moderate expansion, which usually favors entrants that can slot into existing clinical workflows rather than needing new reimbursement behavior. For ZSFab, that makes execution risk look more commercial and regulatory than market-creation driven [Grand View Research] [ZSFab, October 2026].
Demand drivers are fairly straightforward from the cited record, even if the company-specific evidence is thin. ZSFab's positioning centers on personalized implants, surgical guides, and anatomical models produced with software and 3D printing, and its spine products are framed around bone integration, stress distribution, and postoperative imaging visibility [LinkedIn, retrieved 2026] [ZSFab, retrieved 2026]. In market terms, that maps to a persistent clinical preference for implants that can improve fit, support fusion outcomes, and give surgeons more procedural planning tools, especially in spine, where anatomy and pathology vary case by case. The open sales and instrument-development roles on ZSFab's career page also suggest a surgeon-led adoption motion rather than a direct-to-patient one, which is consistent with how spinal hardware is typically specified and sold in the U.S. hospital channel [ZSFab, October 2026].
The adjacent markets are also worth separating, because they shape upside without all belonging to the same budget line. ZSFab's product descriptions extend beyond spinal cages to hip implants, acetabular cups, vertebral-body implants, surgical guides, and anatomical models, which puts it near orthopedic reconstruction and preoperative planning as well as spine hardware [CB Insights] [LinkedIn, retrieved 2026]. Those adjacencies matter because anatomical models and guides can function as lower-friction entry points into hospital relationships, while vertebral-body and other patient-specific implants point toward more customized, case-driven revenue opportunities if regulatory and surgeon adoption hurdles are cleared [CB Insights] [ZSFab, retrieved 2026].
Regulation is the central market filter. In this category, product demand alone does not create revenue unless implants secure clearance and then move through hospital value analysis, surgeon preference, and distributor or direct-sales execution. ZSFab says it received FDA 510(k) clearance for its 3D-Printed Lumbar Interbody System and has announced first U.S. clinical use for certain spinal systems, but much of that evidence is company-published, with limited independent corroboration from trade outlets for some clinical-use announcements [ZSFab, retrieved 2026] [BioSpace, April 2023] [RegMedNet] [Synapse, June 2024]. That leaves the market opportunity intact, but it also means the practical addressable market depends less on headline category size than on a narrow sequence of regulatory, clinical, and commercial milestones.
Partially corroborated -- Market size and North America share are supported by third-party reports, but segment dominance and several company-specific market claims rely on company materials or partial corroboration.
Competition and Substitutes
MIXED ZSFab is positioned against large spine-implant incumbents on one side and narrower spine specialists on the other, with its clearest wedge in patient-specific and 3D-printed interbody devices rather than breadth of catalog [LinkedIn, retrieved 2026] [ZSFab, October 2026].
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| ZSFab | Patient-specific orthopedic and spinal implants, surgical guides, and anatomical models, with current U.S. hiring centered on lumbar TLIF/PLIF and cervical ACDF cages | Seed, about $2.5M disclosed | Customized 3D-printed implants and proprietary algorithmic design claims for patient-matched vertebral-body implants | [CB Insights, retrieved 2026] [Caplight, retrieved 2026] [ZSFab, October 2026] [ZSFab, retrieved 2026] |
| Medtronic | Global medical device incumbent with a spine business | Public company | Scale, surgeon relationships, and broad product portfolio across spine procedures | [Craft.co, retrieved 2026] |
| DePuy Synthes | Large orthopedic and spine incumbent within Johnson & Johnson MedTech | Corporate division of public company | Deep hospital access and established orthopedic distribution infrastructure | [Craft.co, retrieved 2026] |
| Stryker | Large orthopedic and spine incumbent | Public company | Existing hospital procurement footprint and broad musculoskeletal product coverage | [Craft.co, retrieved 2026] |
| Globus Medical | Spine-focused public company | Public company | Category focus in spine rather than a broad medtech portfolio | [Craft.co, retrieved 2026] |
| NuVasive | Spine-focused incumbent competitor | Public company | Existing specialization in spine procedures and surgeon call-point familiarity | [Craft.co, retrieved 2026] |
The competitive map splits three ways. First are diversified incumbents such as Medtronic, DePuy Synthes, and Stryker, which compete on breadth, existing hospital contracts, and surgeon coverage rather than on a single implant architecture [Craft.co, retrieved 2026]. Second are spine-focused specialists such as Globus Medical and NuVasive, where the contest is closer to ZSFab's core segment because purchasing decisions sit with the same surgeon base and procedure set [Craft.co, retrieved 2026] [ZSFab, October 2026]. Third are earlier or narrower challengers named in company-database profiles, including Genysys Spine and NovApproach Spine, although the supplied public record here gives far less detail on their financing or commercial reach than it does for the larger public companies [Tracxn, retrieved 2026] [Craft.co, retrieved 2026].
ZSFab's present edge appears product-specific, not channel-led. The company publicly emphasizes customized implants, proprietary algorithms for patient-matched vertebral-body designs, and digitally structured materials intended to tune porosity and mechanical properties [ZSFab, retrieved 2026]. That can matter in a spine market where lumbar and cervical cage segments are described as the dominant product categories, because a focused entrant does not need to match an incumbent's full line to be relevant in operating rooms if it can win a narrow set of indications and surgeons [ZSFab, retrieved 2026] [Grand View Research, retrieved 2026]. The durability of that edge is still uncertain: design software and additive-manufacturing know-how can support differentiation, but without disclosed evidence of broad installed distribution, named hospital accounts, or a larger funding base, the advantage looks perishable if larger competitors replicate similar 3D-printed offerings or outspend on sales coverage [CB Insights, retrieved 2026] [Caplight, retrieved 2026].
The exposure is easier to see than the moat. Medtronic, Stryker, and DePuy Synthes each begin with established procurement relationships and field organizations that a seed-stage company does not appear to have matched publicly [Craft.co, retrieved 2026] [CB Insights, retrieved 2026]. Globus Medical and NuVasive present a more direct product-line threat because they are closer to ZSFab's procedural focus in spine, which narrows the room for a newcomer to compete on familiarity alone [Craft.co, retrieved 2026]. ZSFab is also exposed outside its chosen wedge: nothing in the public record here suggests it can contest broad orthopedic portfolios, navigation ecosystems, or enterprise contracting motions across hospitals at the level of the largest incumbents [LinkedIn, retrieved 2026] [ZSFab, October 2026].
Over the next 18 months, the most plausible scenario is a share test inside a narrow U.S. spine-commercialization window rather than a category reset. Winner if X: ZSFab, if surgeon-led adoption of its lumbar and cervical cages converts into repeat procedural use after the early clinical-use announcements and current sales hiring push, because a focused company can matter in spine with a small number of strong accounts before it matters nationally [BioSpace, April 2023] [Synapse, June 2024] [ZSFab, October 2026]. Loser if Y: ZSFab, if hospitals and surgeons continue to favor incumbent vendors for bundled purchasing, training, and rep support, in which case Globus Medical or Medtronic are better placed to absorb demand for similar procedures without needing customers to add a new platform [Craft.co, retrieved 2026].
Reasoned from indirect evidence -- Competitive names are confirmed in public company-profile sources, but most positioning detail for ZSFab rests on company materials and databases rather than two-source independent corroboration.
Opportunity
Upside case
PUBLIC The prize here is not a single implant line, but a software-informed spine platform that turns patient-specific design and 3D printing into a repeatable way to win share in one of medtech's larger device categories, where the global spinal implants and devices market was valued at $14.5 billion in 2025 and projected to reach $23.1 billion by 2033 [Grand View Research].
The headline opportunity is straightforward. If ZSFab can move from early clinical use and limited disclosed financing into repeatable U.S. surgeon adoption, it could become a focused challenger in spinal interbody devices, then broaden into adjacent personalized implants and surgical planning products [BioSpace, April 2023] [RegMedNet] [Synapse, June 2024] [CB Insights]. That is reachable, not merely aspirational, because the company appears to have assembled the core ingredients already visible in public records: a commercial focus on lumbar TLIF/PLIF and cervical ACDF cages in the U.S., a 510(k)-cleared lumbar interbody system according to the company, and a product stack that combines implant design, porous architecture control, and patient-matched workflows rather than selling a generic printed part alone [ZSFab, October 2026] [ZSFab] [LinkedIn].
The growth paths are still conditional, but the contours are visible in the current product and hiring posture.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Focused spine specialist winner | ZSFab becomes a recognized niche supplier of 3D-printed cervical and lumbar cages for surgeons who want differentiated geometry and imaging characteristics | Broader U.S. clinical adoption following early reported cases and commercialization hiring [BioSpace, April 2023] [Synapse, June 2024] [ZSFab, October 2026] | The company is already marketing both ACDF and TLIF/PLIF cage categories in the U.S., and lumbar and cervical cages are described as the dominant product segments in spine by product type [ZSFab, October 2026] [ZSFab] |
| Personalized reconstruction platform | The company expands from standard interbody systems into higher-value patient-matched vertebral-body implants, guides, and anatomical models for complex cases | More surgeon-led design wins and proof that proprietary algorithms shorten customization cycles [ZSFab] [LinkedIn] | Public materials already describe vertebral-body implants, surgical guides, and proprietary algorithms for patient-matched implants with customized lattice structures [CB Insights] [ZSFab] |
| Strategic acquisition target in spine | A larger orthopedic or spine incumbent acquires the platform to add additive-manufacturing capability and personalized workflows | Evidence of regulatory progress, clinical use, and a growing U.S. commercial footprint [BioSpace, April 2023] [Synapse, June 2024] [ZSFab, October 2026] | The competitive set includes strategic buyers with established spine franchises, including Medtronic, DePuy Synthes, Stryker, NuVasive, and Globus Medical, all of which operate in categories ZSFab is targeting [Craft.co] [CB Insights] |
These scenarios all depend on the same compounding mechanism. A spine company like this can strengthen its position each time a surgeon uses the system, because clinical familiarity improves sales efficiency, instrument feedback improves future designs, and patient-specific workflow software becomes more useful as the library of use cases expands. ZSFab's public materials suggest the beginnings of that loop already: the company is hiring both a spinal implant instruments development engineer and a U.S. medical device sales representative, which points to parallel investment in surgeon workflow and field commercialization rather than R&D in isolation [ZSFab, October 2026].
The more durable version of that flywheel would pair device revenue with design know-how. If ZSFab's claimed capabilities in porous structure tuning, image clarity, and patient-matched vertebral-body design hold up in broader use, each successful case could improve surgeon trust and make adjacent products easier to place within the same account [ZSFab] [RegMedNet]. In medtech, that kind of account-level layering matters because implants, guides, and planning tools can reinforce one another even without a classic consumer-style network effect.
The size of the win is best framed against category economics rather than current company scale. North America accounted for 48.3% of the spinal implants market in 2022 according to MarketsandMarkets, and the overall category is large enough that even low-single-digit niche penetration can support meaningful enterprise value [MarketsandMarkets] [Grand View Research]. If a scenario in which ZSFab becomes a credible U.S. spine specialist played out and it captured 0.25% to 0.5% of the projected 2033 global spinal implants and devices market, that would imply roughly $57.8 million to $115.5 million in annual category revenue equivalent (estimated), calculated as 0.25% to 0.5% of $23.1 billion [Grand View Research]. At medtech revenue multiples that strong strategic assets can command, the upside could be material, but that valuation framing is a scenario, not a forecast.
Claim stands unchecked -- This section relies on a mix of third-party market data and company-published product, regulatory, and commercialization claims; the material premises around product capability and FDA status are not yet corroborated by two independent public sources.
Sources
Open sources
[Crunchbase, retrieved 2026] ZSFab - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/zsfab
[Swissnex, February 2022] TechTalk: Pitching in China as a technopreneur | https://swissnex.org/china/event/techtalk-pitching-in-china-as-a-technopreneur/
[Caplight, retrieved 2026] ZSFab | https://www.caplight.com/company/zsfab
[CB Insights, retrieved 2026] ZSFab | https://www.cbinsights.com/company/zsfab
[LinkedIn, retrieved 2026] ZSFab | LinkedIn | https://www.linkedin.com/company/zsfab
[ZSFab, October 2026] Career-ZSFab | https://www.zsfab.com/Career
[ZSFab, retrieved 2026] ZSFab | https://www.zsfab.com/
[Kai Xu - Graduate Intern (thesis) - Turner & Townsend | LinkedIn, retrieved 2026] Kai Xu - Graduate Intern (thesis) - Turner & Townsend | LinkedIn | https://www.linkedin.com/in/kai-xu
[BioSpace, April 2023] ZSFab Cervical Interbody System Successfully Used in First Clinical Case in the U.S. | https://www.biospace.com/zsfab-cervical-interbody-system-successfully-used-in-first-clinical-case-in-the-u-s
[RegMedNet, retrieved 2026] ZSFab Cervical Interbody System successfully applied in two US clinical cases | https://www.regmednet.com/zsfab-cervical-interbody-system-successfully-applied-in-two-us-clinical-cases/
[Yahoo Finance, retrieved 2026] ZSFab Announces First Clinical Use of 20° Hyperlordotic Cervical Cages in Puerto Rico | https://finance.yahoo.com/news/zsfab-announces-first-clinical-20-130000000.html
[Synapse, June 2024] ZSFab Announces First U.S. Clinical Use of InterConnect 3D Printed Ti Lumbar Interbody System | https://synapse.patsnap.com/article/zsfab-announces-first-us-clinical-use-of-interconnect-3d-printed-ti-lumbar-interbody-system
[Grand View Research, retrieved 2026] Spinal Implants And Devices Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/spinal-implants-devices-market
[MarketsandMarkets, retrieved 2026] Spinal Implants Market | https://www.marketsandmarkets.com/Market-Reports/spinal-implants-market-712.html
[Craft.co, retrieved 2026] ZSFab Company Profile - Office Locations, Competitors, Revenue, Financials, Employees, Key People, Subsidiaries | https://craft.co/zsfab
[Tracxn, retrieved 2026] ZSFab - 2026 Company Profile, Team, Funding & Competitors | https://tracxn.com/d/companies/zsfab/__Rf1aKajCm5M1NQTUPQmle9m_SdcEWinjvNLWCzWRkb0
Articles about ZSFab
- ZSFab's FDA-Cleared Cages Are a 3D-Printed Wedge Into the Spine Market — The Waltham startup has secured 510(k) clearance and begun initial clinical use, aiming to personalize a field dominated by off-the-shelf devices.